MOLN Latest Press Releases

-- October 22, 2026 --

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 Globe Newswire 1:00 AM

-- August 25, 2026 --

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study Globe Newswire 1:00 AM

-- July 16, 2026 --

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma Globe Newswire 1:00 AM

-- July 15, 2026 --

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference Globe Newswire 1:00 AM

-- July 6, 2026 --

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics Globe Newswire 1:00 AM

-- July 2, 2026 --

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 Globe Newswire 1:00 AM

-- May 30, 2026 --

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes